Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: A literature review
L Belgioia, I Desideri, A Errico, C Franzese… - Critical Reviews in …, 2019 - Elsevier
… -II trial evaluated the effect of erlotinib plus standard radiochemotherapy (cisplatin) on 204
… In a phase-II study, 33 elderly patients were treated with erlotinib and RT, showing a median …
… In a phase-II study, 33 elderly patients were treated with erlotinib and RT, showing a median …
Erlotinib versus etoposide/cisplatin with radiation therapy in unresectable stage III epidermal growth factor receptor mutation-positive non-small cell lung cancer: a …
L Xing, G Wu, L Wang, J Li, J Wang, Z Yuan… - International Journal of …, 2021 - Elsevier
… Concurrent chemoradiotherapy (CCRT) is the standard of … study, we investigated the efficacy
and tolerability of erlotinib … RT, for unresectable stage III NSCLC patients with an activating …
and tolerability of erlotinib … RT, for unresectable stage III NSCLC patients with an activating …
Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase …
C Xie, Z Jing, H Luo, W Jiang, L Ma, W Hu… - British Journal of …, 2020 - nature.com
… ) plus erlotinib; B: radiotherapy adoption of ENI with two cycles of concurrent TP; C: radiotherapy
… The comparison revealed that ENI significantly prolonged OS and PFS compared with …
… The comparison revealed that ENI significantly prolonged OS and PFS compared with …
Comparison of concurrent chemoradiation with daily gefitinib versus daily erlotinib in locally advanced oropharyngeal cancers.
P Nagpal, U Suryanarayana, D Pruthi… - … Investigation …, 2021 - search.ebscohost.com
… (elderly patients or those with deranged kidney function tests).[5] These drugs enhance
the sensitivity of tumor cells to radiotherapy … Radiotherapy plus cetuximab for squamous‑cell …
the sensitivity of tumor cells to radiotherapy … Radiotherapy plus cetuximab for squamous‑cell …
Icotinib with concurrent radiotherapy vs radiotherapy alone in older adults with unresectable esophageal squamous cell carcinoma: a phase II randomized clinical trial
H Luo, W Jiang, L Ma, P Chen, M Fang… - JAMA Network …, 2020 - jamanetwork.com
… The pilot study of erlotinib plus RT revealed a 2-year survival rate of 44.4% with a … We
did a stratified log-rank comparison of OS in the intention-to-treat population. Univariate and …
did a stratified log-rank comparison of OS in the intention-to-treat population. Univariate and …
… inhibitors combined with thoracic radiotherapy or chemoradiotherapy for advanced or metastatic non-small cell lung cancer: A systematic review and meta-analysis of …
R Liu, S Wei, Q Zhang, X Zhang, H Luo, J Tian, Y Li… - Medicine, 2019 - journals.lww.com
… We acknowledge that the evidence of single arms without comparative data is associated …
The Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with …
The Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with …
[HTML][HTML] Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial
Y Liu, Y Cheng, K Li, J Shi, Y Liu, L Wu… - … Cancer Research, 2021 - ncbi.nlm.nih.gov
… comparison of the results of the present study with the published findings was limited by the
fact that no similar study comparing … Concurrent chemoradiotherapy can be used in patients …
fact that no similar study comparing … Concurrent chemoradiotherapy can be used in patients …
Efficacy and safety of EGFR inhibitors and radiotherapy in locally advanced non-small-cell lung cancer: a meta-analysis
X Li, F Wang, H Jia, Z Lian, K Ren, Z Yuan… - Future …, 2022 - Future Medicine
… A phase II study showed that the incidence of AEs was similar between erlotinib + radiotherapy
and concurrent chemoradiotherapy groups [44]. In this study, the most common severe …
and concurrent chemoradiotherapy groups [44]. In this study, the most common severe …
Radiotherapy and receptor tyrosine kinase inhibition for solid cancers (ROCKIT): a meta-analysis of 13 studies
LT Tchelebi, E Batchelder, M Wang… - JNCI Cancer …, 2021 - academic.oup.com
… On subgroup analysis of patients receiving antibody RTKi, the hazard ratio for chemoradiotherapy
or radiotherapy plus RTKi vs … (10) study, which analyzed the addition of erlotinib to …
or radiotherapy plus RTKi vs … (10) study, which analyzed the addition of erlotinib to …
Safety of radiotherapy with concurrent docetaxel in older patients with esophageal cancer
T Kawamoto, N Shikama, M Oshima, Y Kosugi… - Journal of Geriatric …, 2020 - Elsevier
… 84 older adult patients receiving radical radiotherapy or chemoradiotherapy, 73 receiving
DOC-RT were studied. … When comparing our results with those of other similar studies, three …
DOC-RT were studied. … When comparing our results with those of other similar studies, three …